These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 23230972

  • 1. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.
    Hammond SP, Martin ST, Roberts K, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR.
    Transpl Infect Dis; 2013 Apr; 15(2):163-70. PubMed ID: 23230972
    [Abstract] [Full Text] [Related]

  • 2. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG, Weill D, Gupta MR, Raper B, Laplace SG, Lombard GA, Bonvillain RW, Taylor DE, Dhillon GS.
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [Abstract] [Full Text] [Related]

  • 3. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC.
    Transplantation; 2006 May 27; 81(10):1415-20. PubMed ID: 16732179
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.
    Clin Transplant; 2013 May 27; 27(4):503-9. PubMed ID: 23731387
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E, Lesnick T, Kremers W, Kennedy CC, Razonable RR.
    Clin Transplant; 2016 Mar 27; 30(3):270-8. PubMed ID: 26701733
    [Abstract] [Full Text] [Related]

  • 6. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant Group.
    Transpl Infect Dis; 2018 Oct 27; 20(5):e12964. PubMed ID: 29981174
    [Abstract] [Full Text] [Related]

  • 7. Epidemiology of cytomegalovirus infection after pancreas transplantation.
    Parsaik AK, Bhalla T, Dong M, Rostambeigi N, Dierkhising RA, Dean P, Abraham R, Prieto M, Kremers WK, Razonable RR, Kudva YC.
    Transplantation; 2011 Nov 15; 92(9):1044-50. PubMed ID: 21904269
    [Abstract] [Full Text] [Related]

  • 8. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.
    Transpl Infect Dis; 2020 Aug 15; 22(4):e13277. PubMed ID: 32170813
    [Abstract] [Full Text] [Related]

  • 9. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 15; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 10. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar 15; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 11. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.
    Clin Transplant; 2004 Apr 15; 18(2):179-85. PubMed ID: 15016133
    [Abstract] [Full Text] [Related]

  • 12. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
    Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP.
    Transpl Infect Dis; 2020 Jun 15; 22(3):e13255. PubMed ID: 32020736
    [Abstract] [Full Text] [Related]

  • 13. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V.
    Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451
    [Abstract] [Full Text] [Related]

  • 14. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999.
    Smits JM, Vanhaecke J, Haverich A, de Vries E, Smith M, Rutgrink E, Ramsoebhag A, Hop A, Persijn G, Laufer G.
    Clin Transpl; 2003 Feb 15; ():89-100. PubMed ID: 15387100
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection in living-donor and cadaveric lung transplantations.
    Ohata K, Chen-Yoshikawa TF, Takahashi K, Aoyama A, Motoyama H, Hijiya K, Hamaji M, Menju T, Sato T, Sonobe M, Takakura S, Date H.
    Interact Cardiovasc Thorac Surg; 2017 Nov 01; 25(5):710-715. PubMed ID: 29049752
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.
    Johanssson I, Mårtensson G, Andersson R.
    Scand J Infect Dis; 2010 Nov 01; 42(2):129-36. PubMed ID: 20082575
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 01; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 18. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD.
    Transplantation; 2006 Apr 27; 81(8):1106-11. PubMed ID: 16641594
    [Abstract] [Full Text] [Related]

  • 19. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction.
    Walker JK, Scholz LM, Scheetz MH, Gallon LG, Kaufman DB, Rachwalski EJ, Abecassis MM, Leventhal JR.
    Transplantation; 2007 Apr 15; 83(7):874-82. PubMed ID: 17460557
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, Sardana R, Lal N, Kumar A.
    Liver Transpl; 2012 Dec 15; 18(12):1448-55. PubMed ID: 22903934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.